null Michael Sebag, MD, PhD

Scientist, RI-MUHC, Glen site

Cancer Research Program

Centre for Translational Biology

Associate Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Hematology, MUHC



multiple myeloma • hematologic malignancies • tumor microenvironment • drug development • clinical trials

Research Focus

My research focuses on the second most common hematologic malignancy in adults, multiple myeloma. We focus on bench to bedside research with emphasis on both basic science and clinical trials in multiple myeloma. In the lab we are focusing on the impact of the microenvironment on the development and progression of multiple myeloma. We are looking at the role of the multiple myeloma cell in osteoblastic development and its impact on multiple myeloma bone disease. We are working on novel agents which target either the myeloma cell directly or its microenvironment with the aid of a novel transgenic model of multiple myeloma.

Selected Publications

Click on Pubmed to see my current publications list

  • Robert F, Roman W, Bramoullé A, Fellmann C, Roulston A, Shustik C, Porco JA Jr, Shore GC, Sebag M, Pelletier J. Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13421-6. doi: 10.1073/pnas.1402650111. Epub 2014 Sep 2. PMID: 25197055.

  • Leung CY, Park J, De Schutter JW, Sebag M, Berghuis AM, Tsantrizos YS. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition. J Med Chem. 2013 Oct 24;56(20):7939-50. doi: 10.1021/jm400946f. Epub 2013 Oct 3. PMID: 23998921.

  • Sebag M. CCR1 blockade and myeloma bone disease. Blood. 2012 Aug 16;120(7):1351-2. doi: 10.1182/blood-2012-06-434019. PMID: 22899473.

  • Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14;119(24):5661-70. doi: 10.1182/blood-2012-03-414359. Epub 2012 May 3. PMID: 22555973.

  • Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, Fonseca R, Kremer R, Cattoretti G, Bergsagel PL. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008 Feb;13(2):167-80. doi: 10.1016/j.ccr.2008.01.007. PMID: 18242516.